Education
About Us
Working with TipRanks
Follow Us
Orgenesis (ORGS)
:ORGS
ORGS Stock Chart & Stats
$0.15
$0.04(1.86%)
At close: 4:00 PM EST
$0.15
$0.04(1.86%)
Day’s Range― - ―
52-Week Range$0.02 - $5.89
Previous CloseN/A
Volume307.00
Average Volume (3M)1.14K
Market Cap
$775.39K
Enterprise ValueN/A
Total Cash (Recent Filing)$204.00K
Total Debt (Recent Filing)$17.30M
Price to Earnings (P/E)―
Beta-6.21
Next Earnings
Nov 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,169,248
10 Day Avg. Volume1,067
30 Day Avg. Volume1,137
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-6.91
Price to Sales (P/S)273.66
P/FCF Ratio-8.57
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Orgenesis News
ORGS FAQ
What was Orgenesis’s price range in the past 12 months?
Orgenesis lowest stock price was $0.02 and its highest was $5.89 in the past 12 months.
What is Orgenesis’s market cap?
Orgenesis’s market cap is $775.39K.
When is Orgenesis’s upcoming earnings report date?
Orgenesis’s upcoming earnings report date is Nov 07, 2025 which is in 6 days.
How were Orgenesis’s earnings last quarter?
Currently, no data Available
Is Orgenesis overvalued?
According to Wall Street analysts Orgenesis’s price is currently Overvalued.
Does Orgenesis pay dividends?
Orgenesis does not currently pay dividends.
What is Orgenesis’s EPS estimate?
Orgenesis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orgenesis have?
Orgenesis has 5,169,248 shares outstanding.
What happened to Orgenesis’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Orgenesis?
Currently, no hedge funds are holding shares in ORGS
Company Description
Orgenesis
Orgenesis Inc. (ORGS) is a global biotech company that specializes in cell and gene therapy manufacturing and development. The company is focused on advancing its Point-of-Care (POCare) platform, which aims to bring personalized cell and gene therapies directly to patients through a decentralized production model. Orgenesis operates within the biotechnology and healthcare sectors, providing a range of services and technologies designed to streamline the development and commercialization of advanced therapeutics.
Technical Analysis
Scinai Immunotherapeutics
―
GT Biopharma
―
Aditxt
―
Psyence Biomedical
―
Conduit Pharmaceuticals
―